Bris­tol-My­ers Squib­b's Op­di­vo could­n't top­ple Nex­avar in HCC — but will bet­ter safe­ty pro­file win over physi­cians?

BARCELONA — Bris­tol-My­ers Squibb’s Op­di­vo couldn’t quite beat Nex­avar, the stan­dard of care in he­pa­to­cel­lu­lar car­ci­no­ma, in its Phase III head-to-head. But in­ves­ti­ga­tors are still hop­ing that it can play a role in the front­line set­ting of this dis­ease.

Thomas Yau of the Uni­ver­si­ty of Hong Kong, who led the Check­mate-459 study, hit hard on Op­di­vo’s “clin­i­cal­ly mean­ing­ful” ad­van­tages over the en­trenched ther­a­py, par­tic­u­lar­ly in terms of side ef­fects and qual­i­ty of life.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters